Most cited papers from Ipsen (Germany)

Ipsen (Germany)

What are the most cited papers from Ipsen (Germany)?

The most cited paper from Ipsen (Germany) is "Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study" (Guillaume Nicolas, N. Schreiter, Felix Kaul et al., 2017), with 169 citations. Next come "Biodistribution, Pharmacokinetics, and Dosimetry of 177 Lu-, 90 Y-, and 111 In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177 Lu-DOTATATE: The Mass Effect" (151) and "Classification of posture in poststroke upper limb spasticity" (120).

Published TypeFieldAccessCitations

Showing 50 of 88 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study Guillaume Nicolas, N. Schreiter, Felix Kaul et al. · Journal of Nuclear Medicine Open access	30 Nov 2017	169
2	Biodistribution, Pharmacokinetics, and Dosimetry of 177 Lu-, 90 Y-, and 111 In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177 Lu-DOTATATE: The Mass Effect Guillaume Nicolas, Rosalba Mansi, Lisa McDougall et al. · Journal of Nuclear Medicine Open access	27 Apr 2017	151
3	Classification of posture in poststroke upper limb spasticity Harald Hefter, Wolfgang H. Jost, Andrea Reissig et al. · International Journal of Rehabilitation Research	2 May 2012	120
4	Ultra-High-Dose Lanreotide Treatment in Patients with Metastatic Neuroendocrine Gastroenteropancreatic Tumors Siegbert Faiss, U. Räth, Ulrich Mansmann et al. · Digestion	1999	117
5	Treatment of adductor spasticity with BTX‐A in children with CP: a randomized, double‐blind, placebo‐controlled study Volker Mall, Andrea Siebel, Christoph Bertram et al. · Developmental Medicine & Child Neurology	19 Dec 2005	103
6	Safety, Biodistribution, and Radiation Dosimetry of 68 Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study Guillaume Nicolas, Seval Beykan, Hakim Bouterfa et al. · Journal of Nuclear Medicine Open access	12 Oct 2017	92
7	Hemodiafiltration to Address Unmet Medical Needs ESKD Patients Bernard Canaud, Jörg Vienken, Stephen R. Ash et al. · Clinical Journal of the American Society of Nephrology Open access	6 Mar 2018	75
8	New developments in thermo-chemical diffusion processes Winfried Gräfen, Bernd Edenhofer · Surface and Coatings Technology	26 Oct 2005	70
9	The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ) Michael J. Alexander, William E. Berger, P. Buchholz et al. · Health and Quality of Life Outcomes Open access	31 Oct 2005	60
10	Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Kai Wohlfarth, Thomas Sycha, Danièle Ranoux et al. · Current Medical Research and Opinion	22 May 2009	59
11	Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR Jochen Schopohl, C. J. Strasburger, David M. Caird et al. · Experimental and Clinical Endocrinology & Diabetes	17 Nov 2010	53
12	Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German–Austrian open-label post-marketing surveillance prospective study Wolfgang H. Jost, Harald Hefter, Andrea Reissig et al. · Journal of the Neurological Sciences Open access	22 Nov 2013	50
13	In Vivo Biokinetics of 177Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry Seval Beykan, Melpomeni Fani, Svend Borup Jensen et al. · Contrast Media & Molecular Imaging Open access	3 Jan 2019	49
14	Regulatory Considerations for Hemodiafiltration in the United States Richard A. Ward, Jörg Vienken, Douglas M. Silverstein et al. · Clinical Journal of the American Society of Nephrology Open access	6 Mar 2018	38
15	Plasma-carburising — a surface heat treatment process for the new century Bernd Edenhofer, Winfried Gräfen, J Müller-Ziller · Surface and Coatings Technology	Jul 2001	38
16	Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes Marie Christine Hupe, Peter G. Hammerer, Miriam Ketz et al. · Frontiers in Oncology Open access	27 Nov 2018	34
17	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment Jörg Wissel, Klemens Fheodoroff, Maurits H. J. Hoonhorst et al. · Frontiers in Neurology Open access	28 Feb 2020	31
18	Impaired hemodynamics and neural activation? Margret Hund‐Georgiadis, Toralf Mildner, Dimosthenis Georgiadis et al. · Neurology Open access	11 Nov 2003	30
19	Hip Lateralisation in Children with Bilateral Spastic Cerebral Palsy Treated with Botulinum Toxin Type A: A 2-Year Follow-Up Nikolai H. Jung, Florian Heinen, Bettina Westhoff et al. · Neuropediatrics	Feb 2011	22
20	Efficacy of BTX/A in the treatment of adductor spasticity: a randomized, double blinded, placebo-controlled trial Volker Mall, Florian Heinen, Andrea Siebel et al. · Neuropediatrics	4 Mar 2004	21
21	Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III for the OPTIC III Study Group, Thorsten Bach, Patrick J. Bastian et al. · World Journal of Urology Open access	30 Aug 2016	19
22	177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model Seval Beykan, Jan S. Dam, Uta Eberlein et al. · EJNMMI Research Open access	13 Jun 2016	19
23	Heat transfer from typical loads within gas quenching furnace Olivier Macchion, Said Zahrai, J. W. Bouwman · Journal of Materials Processing Technology	7 Jan 2006	16
24	Comparison of type a botulinum toxin products in clinical use Andrew M. Pickett, David M. Caird · Journal of Clinical Pharmacy and Therapeutics Open access	30 Apr 2008	15
25	Professional Assessment of the Impact of COVID-19 on Handling NET Patients Sebastian Krug, Jakob Garbe, Senta König et al. · Journal of Clinical Medicine Open access	11 Nov 2020	14
26	Longitudinal Goal Attainment With Repeat Injections of AbobotulinumtoxinA in Adults With Lower Limb Spasticity: Results From a Prospective Observational Study Alberto Esquenazi, Richard D. Zorowitz, Stephen A. Ashford et al. · Archives of Physical Medicine and Rehabilitation Open access	19 Nov 2024	13
27	Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study Marianne Ellen Pavel, Harald Lahner, Dieter Hörsch et al. · The Oncologist Open access	11 Jan 2024	11
28	Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland Sylvère Störmann, Jochen Schopohl, Catharina Bullmann et al. · Experimental and Clinical Endocrinology & Diabetes Open access	7 Dec 2020	10
29	Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB Tilman Todenhöfer, Moritz Maas, Miriam Ketz et al. · World Journal of Urology Open access	10 Feb 2021	9
30	Muscle selection and dosing in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in real-world practice Richard D. Zorowitz, Jorge Jacinto, Stephen A. Ashford et al. · Journal of Rehabilitation Medicine Open access	7 Feb 2025	7
31	1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC) L. Albiges, T.B. Powles, Ashish Sharma et al. · Annals of Oncology Open access	Sep 2024	7
32	Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study Wolfgang H. Jost, Axel Schramm, Martina Müngersdorf et al. · Journal of the Neurological Sciences Open access	10 Feb 2019	7
33	Budget impact of botulinum toxin treatment for spasticity after stroke — a German perspective Silke Neusser, Cordula Charlotte Josefine Kreuzenbeck, Kathrin Pahmeier et al. · Journal of Public Health Open access	28 Nov 2019	6
34	Retrospektive GKV-Versorgungsforschungsstudie über GnRH-Antagonisten/-Agonisten zur initialen Therapie des fortgeschrittenen Prostatakarzinoms – Verordnungsmuster und Krankenhauskosten in Deutschland Marie Christine Hupe, Peter G. Hammerer, Miriam Ketz et al. · Aktuelle Urologie Open access	19 Nov 2019	6
35	Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria Anja Rinke, Christoph Maintz, Lothar Müller et al. · Experimental and Clinical Endocrinology & Diabetes Open access	Jul 2021	5
36	Kosten-Effektivitäts-Analyse zur Verwendung der Blaulichtzystoskopie mit Hexylaminolevulinat bei der transurethralen Resektion der Harnblase Georgios Gakis, B. Volkmer, Bryan Qvick et al. · Der Urologe	10 Apr 2018	5
37	Lebensqualität von Patienten mit Prostatakarzinom unter Androgendeprivation mit GnRH-Analoga TRIPTOSIX-Studiengruppe, A. Eisenhardt, Tim Schneider et al. · Der Urologe	30 Oct 2015	5
38	CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma Laurence K. Albiges, Thomas Powles, Anand Sharma et al. · European Urology Open access	30 Sep 2025	4
39	Odevixibat after liver transplant in patients with progressive familial intrahepatic cholestasis type 1: A case series Georg Friedrich Vogel, Simone Kathemann, Andrea Pietrobattista et al. · Journal of Pediatric Gastroenterology and Nutrition Open access	5 Oct 2025	3
40	CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma Philippe Barthélémy, Pascale Dutailly, Bryan Qvick et al. · Future Oncology Open access	5 Jul 2023	3
41	Selective surface densification for high performance P/M components Lorenz S. Sigl, Pmg F	2012	3
42	Longitudinal, Multi-Cycle Evaluation of Passive Function Improvement in People with Arm Spasticity Treated with Botulinum Toxin A Stephen A. Ashford, Khan Buchwald, Klemens Fheodoroff et al. · Toxins Open access	19 Jan 2026	2
43	Odevixibat treatment in a child with hypoplastic left heart syndrome and severe cholestatic pruritus: a case report Rainer Ganschow, Christof Maucksch, Peter Rauschkolb et al. · Frontiers in Pediatrics Open access	23 Jan 2025	2
44	Therapieziele bei Patienten mit Armspastik nach Schlaganfall nach Injektion mit Botulinumtoxin A Klemens Fheodoroff, Dirk W. Dressler, Hartwig Woldag et al. · Der Nervenarzt Open access	15 Oct 2018	2
45	Combined lanreotide autogel and temozolomide therapy in progressive neuroendocrine tumours: the SONNET study Dieter Hörsch, Markus Raderer, Harald Lahner et al. · Annals of Oncology Open access	Oct 2016	2
46	Zirkulardichroismus: Chirale Spektroskopie im IR Hans‐Hermann Drews · Nachrichten aus der Chemie	Sep 2003	2
47	Querschnittsanalyse zur Routinebehandlung von Prostatakrebspatienten Marko Schulze, Hubert Stiegler, C. Thielecke et al. · Der Urologe	Jun 2014	2
48	Behandlungszufriedenheit bei Patienten mit zervikaler Dystonie Chi Wang Ip, Axel Schramm, Pascal Maisonobe et al. · Der Nervenarzt Open access	3 May 2021	1
49	Kommunikationspräferenzen von Patienten mit Prostatakrebs Axel S. Merseburger, Mario W. Kramer, Karl Scheithe et al. · Der Urologe	15 Jun 2016	1
50	Budget Impact Analysis Of Botulinum Toxin A Therapy For Upper Limb Spasticity In Germany YF Zoellner, M. Gerwe, M. Richter · Value in Health Open access	26 Oct 2014	1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.